Mitokinin
Steven Hansberry has three years of work experience in the research field. In 2019, they worked as a Research Associate at Mitokinin Inc. In 2018, they worked as a Staff Research Associate I at UCSF Medical Center. In 2017, they worked as a CIRM Bridges Fellow at the California Institute for Regenerative Medicine. At this position, they aimed to understand the mechanisms behind a severe form of Fibrodysplasia Ossificans Progressiva by using CRISPR to introduce the disease-causing point mutation into wild-type cell lines. Steven also drove forward a secondary project to establish a protocol for 3D culture of murine bone marrow. In 1901, they worked as a Research Associate at San Francisco State University, where they were part of a team which investigated organelle size homeostasis.
Steven Hansberry obtained a Bachelor of Science in Cell/Cellular and Molecular Biology from San Francisco State University in 2016, having started their studies there in 2012. Steven then continued their studies at San Francisco State University and obtained a Master of Science in Biomedical Sciences with a Concentration in Stem Cell Science in 2018.
Mitokinin
Mitokinin is operates in the healthcare industry focusing on biotechnology business. Mitokinin has advanced small molecule therapeutics that specifically increase the activity of active-form PINK1. Importantly, Mitokinin’s compounds do not interfere with the endogenous regulation of PINK1. PINK1 is a master regulator of mitochondrial quality control. Mutations in PINK1 give rise to familial forms of Parkinson’s disease. Increased PINK1 activity rescues pathologies associated with neurodegenerative disease. Mitokinin has an accomplished team of neuroscientists, chemists, pharmacologists, and administrative professionals all focused on our mission: delivering disease-modifying therapies for neurodegenerative disease.